MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
PRNewsWire
·
2026-05-14
·
via The Tech Buzz - Press Releases
- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints i…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。